B. Riley Securities Maintains Buy on Cytokinetics, Lowers Price Target to $92
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has maintained its Buy rating on Cytokinetics (NASDAQ:CYTK) but has lowered the price target from $122 to $92.

June 04, 2024 | 4:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
B. Riley Securities has maintained its Buy rating on Cytokinetics but has lowered the price target from $122 to $92.
The maintained Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates a reassessment of its near-term valuation. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100